JAMMU, Aug 5: Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today announced its financial results for the quarter ended June 30, 2026, reporting its highest-ever quarterly revenue and highest-ever quarterly earnings, supported by better operating leverage, improved performance on API front, strong export growth and full scale commercialization of CDMO mandate.
Revenue: Rs. 575.31 Cr, up 34% YoY, EBITDA: Rs. 87.72 Cr, up 207% YoY, EBITDA Margin: 15.25%, improved from 6.65% in Q1 FY26, PAT: Rs. 56.35 Cr, up 394% YoY, Export Revenue: up 111% YoY, API Growth:31%; API exports up 42%, Medical Devices Growth: 19%, CDMO order: Rs. 825 Cr.
The first quarter also marked a major strategic milestone as Morepen’s previously announced Rs. 825 Cr CDMO mandate entered full scale commercialization phase, with Rs. 58 Cr worth of commercial CDMO dispatches already completed during the quarter. This marks the commercial validation of the Company’s Morepen 2.0 strategy, focused on moving from traditional commodity APIs toward innovation-led manufacturing, long-duration CDMO partnerships, recurring customer programs and a scalable operating platform.
Commenting on the performance, Sushil Suri, Chairman & Managing Director, Morepen Laboratories Limited, said: “Q1 FY27 marks an important validation of Morepen’s transformation journey. The Company has delivered its highest-ever quarterly revenue, strong profitability improvement and meaningful operating leverage. More importantly, our Rs. 825 Cr CDMO mandate has now entered full scale commercial execution, reinforcing our shift from a transaction-led API business to a more focused, manufacturing-led platform built around long-duration global partnerships.”“With API profitability recovering, exports growing strongly and Medical Devices continuing to scale as a second growth engine, Morepen is entering the next phase with greater confidence. Our focus remains on disciplined execution, capacity expansion, customer diversification and building deeper scientific and compliance capabilities to create a stronger, more predictable and globally relevant Morepen.”